Nonetheless, STZ as administered here reduced plasma insulin substantially (by 82–84%), via efficacious reduction in pancreatic β cell mass, and induced hyperglycemia, which are key hallmarks of type 1 diabetes. The gene discussed is INS; the disease is Hyperglycemia.